On a relative basis, the stock has outperformed the S&P 500 by 5.2% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.64% in the last 1 week, and is up 9.8% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock. The stock has recorded a 20-day Moving Average of 11.14% and the 50-Day Moving Average is 9.33%.
BioMarin Pharmaceutical (NASDAQ:BMRN): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $89.79 and $89.19 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $94.75. The buying momentum continued till the end and the stock did not give up its gains. It closed at $92.08, notching a gain of 3.43% for the day. The total traded volume was 2,916,697 . The stock had closed at $89.03 on the previous day.
The company Insiders own 2.5% of BioMarin Pharmaceutical shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -13.41% . During last six month period, the net percent change held by insiders has seen a change of -4.65%. In a related news,The officer (EVP, General Counsel) of Biomarin Pharmaceutical Inc, Davis George Eric sold 2,167 shares at $90 on July 7, 2016. The Insider selling transaction had a total value worth of $195,030. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Companys product portfolio is comprised of five approved products and multiple clinical and pre-clinical product candidates. Its approved products are Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Vimizim received marketing approval in the United States, the European Union and subsequently in several other countries. Naglazyme received marketing approval in the United States, the European Union and subsequently in other countries. Kuvan was granted marketing approval in the United States, the European Union. Aldurazyme, which was developed in collaboration with Genzyme Corporation (Genzyme), was approved for marketing in the United States, the European Union, and subsequently in other countries. Firdapse was approved by the European Medicines Agency (EMA).